Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer.
Angiogenesis is pivotal in the development and progression of ovarian cancer and is an ideal candidate for novel treatment approaches. A case of advanced, recurrent and refractory serous carcinoma is presented that responded to bevacizumab 15 mg/m2 intravenously every 3 weeks after failing eleventh line cytotoxic chemotherapy and radiation. An objective durable response lasting at least 5 months was documented. Bevacizumab has activity in epithelial ovarian carcinoma and larger scale trials are indicated.